Skip to main content
. 2021 May 15;52(2):397–402. doi: 10.1007/s11239-021-02455-x

Table 2.

Pharmacokinetic properties and dosing for the direct oral factor Xa inhibitors

Rivaroxaban Apixaban Betrixaban Edoxaban
Bioavailability  > 80%  > 50%  ~ 35%  > 80%
Onset of action, hrs 2–4  ~ 3 1–3 1–2
Half-life, hrs 5–13 9–14 ~ 20 8–10
Metabolism 1/3 renal; 2/3 liver (CYP 450) Multiple pathways (25% renal) Via bile (~ 5% renal) Multiple (majority renal)
Likehood of drug interactions Low–Mod Low Low Low-Mod
Dosing Oral once daily Oral twice daily Oral once daily Oral once daily